Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guérrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers

• Published in: Transactions of the Royal Society of Tropical Medicine and Hygiene 2003-05, Vol.97 (3), p.365-368
• Main Authors: Kamil, A.A., Khalil, E.A.G., Musa, A.M., Modabber, F., Mukhtar, M.M., Ibrahim, M.E., Zijlstra, E.E., Sacks, D., Smith, P.G., Zicker, F., El-Hassan, A.M.
• Format: Article
• Language: English
• Subjects: Adult; Allergic diseases; alum; Alum Compounds; Animals; Antibodies, Protozoan - immunology; bacille Calmette-Guérrin; BCG Vaccine - administration & dosage; BCG Vaccine - adverse effects; BCG Vaccine - immunology; Biological and medical sciences; Dose-Response Relationship, Immunologic; Female; Human protozoal diseases; Humans; Hypersensitivity, Delayed - immunology; Immunopathology; Infectious diseases; Leishmania major; Leishmania major - immunology; Leishmaniasis Vaccines; Leishmaniasis, Visceral - prevention & control; Leshmaniasis; Male; Medical sciences; Middle Aged; Parasitic diseases; Protozoal diseases; Protozoan Vaccines - administration & dosage; Protozoan Vaccines - adverse effects; Protozoan Vaccines - immunology; Skin allergic diseases. Stinging insect allergies; Skin Tests; Sudan; vaccine; Vaccines, Combined - adverse effects; Vaccines, Combined - immunology; visceral leishmaniasis
• ISSN: 0035-9203; 1878-3503
• DOI: 10.1016/S0035-9203(03)90171-4

In a previous efficacy study, autoclaved Leishmania major (ALM) + bacille Calmette—Guérrin (BCG) vaccine was shown to be safe, but not superior to BCG alone, in protecting against visceral leishmaniasis. From June 1999 to June 2000, we studied the safety and immunogenicity of different doses of alum-precipitated ALM + BCG vaccine mixture administered intradermally to evaluate whether the addition of alum improved the immunogenicity of ALM. Twenty-four healthy adult volunteers were recruited and sequentially allocated to receive either 10 μg, 100 μg, 200 μg, or 400 μg of leishmanial protein in the alum-precipitated ALM + BCG vaccine mixture. Side effects were minimal for all doses and confined to the site of injection. All volunteers in the 10 μg, 100 μg, and 400 μg groups had a leishmanin skin test (LST) reaction of ⩾ 5 mm by day 42 and this response was maintained when tested after 90 d. Only 1 volunteer out of 5 in the 200 μg group had a LST reaction of ⩾ 5mm by day 42 and the reasons for the different LST responses in this group are unclear. This is the first time that an alum adjuvant with ALM has been in used in humans and the vaccine mixture was safe and induced a strong delayed type hypersensitivity (DTH) reaction in the study volunteers. On the basis of this study we suggest that 100 μg of leishmanial protein in the vaccine mixture is a suitable dose for future efficacy studies, as it induced the strongest DTH reaction following vaccination.